Marlborough, Mass. – October 07, 2026 -- Boston Scientific Corporation (NYSE: BSX) has appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective Jan. 1, 2027, a move paired with a restructuring of the company into three reportable business segments.
Boston Scientific splits operations into Interventional Therapies, Rhythm Solutions and MedSurg
The new segment structure takes effect Jan. 1, 2027. Interventional Therapies will combine the Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization businesses, and will absorb the Penumbra business once that acquisition closes. Rhythm Solutions will house Electrophysiology, WATCHMAN, and Cardiac Rhythm Management & Diagnostics. MedSurg will encompass Endoscopy, Urology and Neuromodulation.
Three segment presidents will report directly to incoming COO Fitzgerald
Lance Bates, currently executive vice president and president of Interventional Therapies, will lead that global segment. Nick Spadea-Anello, executive vice president and president of Atrial Fibrillation Solutions, will head Rhythm Solutions. Stephen Morse, senior vice president and president of Asia Pacific, moves up to executive vice president and president of MedSurg and Asia Pacific. All three will report to Fitzgerald, who currently serves as executive vice president and group president of Cardiovascular.
CEO Mahoney frames the overhaul as a bid for faster decision-making
"Joe's deep knowledge of our business and markets, strategic leadership and strong track record of execution make him well suited for this role,